Examination of the excitatory/ inhibitory (E/I) neurotransmitter balance via MRS in patients with substance use disorders

Recruiting

Conditions: healthy volunteers
F11.2
F12.2
F17.2

Registration Number: DRKS00022038

Lead Sponsor: Zentralinstitut für Seelische Gesundheit, Klinik für Abhängiges Verhalten und Suchtmedizin

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

• age: between 25 and 50 years
• Fully Informed Consent
• Ability to undergo fMRI scanning
• Written Informed Consent
• In the clinical groups: diagnosed opiate addiction and opiate substitution treatment or diagnosed cannabis addiction or diagnosed nicotine addiction

Exclusion Criteria

• No Written Informed Consent
• female participants: pregnancy (positive pregnancy test) or currently breastfeeding (anamnestic data)
• Psychiotic disorders or other severe or difficult to manage psychiatric illnesses
• Severe neurological or internal comorbidities
• Psychotropic medication other than antidepressants from the category if SSRIs or Mirtazapin or Pipamperon
• Severe drug consumption in addition to the index drug or acute intoxication
• fMRI contraindications

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
• Measuring the excitatory/ inhibitory balance and resting state activity in the insula and the medial prefrontal cortex using multimodal magnetic resonance spectroscopy (fMRI, MRS, DTI).<br>• Measuring executive functioning performance usnig neuropsychological tests<br>

Secondary Outcome Measures

Name	Time	Method
• Examination of biological markers for alcohol and drug abuse, epigenetic markers, inflammatory markers (IL-1, IL-4, IL-6, IL-8, IL-10, IL-12, TNF-alpha, INF-gamma, MCP-1) and microbiota. <br>